www.itbiznews.com


KLTO and Japan’s Okinawa Research Center for Longevity Science partner to assess alpha-Klotho protein levels in centenarian blood and tissues, investigating how declining expression correlates with age-related pathologies. By leveraging gene therapy to restore secreted Klotho isoform, they aim to mitigate neurological disorders and extend healthspan in humans, building on promising preclinical models.

Key points

  • Quantification of alpha-Klotho and s-KL levels in centenarian blood and tissue via immunoassays.
  • AAV-mediated s-KL gene therapy vectors designed to restore secreted Klotho expression and evaluate neuroprotective efficacy.
  • Correlation analysis between s-KL depletion and onset of ALS, Alzheimer’s, and Parkinson’s, highlighting biomarker and therapeutic potential.

Why it matters: Restoring Klotho levels offers a novel therapeutic strategy to counteract age-related neurodegeneration and extend human healthspan.

Q&A

  • What is alpha-Klotho?
  • What is the secreted Klotho isoform?
  • How is Klotho gene therapy delivered?
  • Why study Okinawan centenarians?
Copy link
Facebook X LinkedIn WhatsApp
Share post via...
Klotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protei